


Ask a doctor about a prescription for Cataflam 50
Diclofenac Potassium
Cataflam 50 contains diclofenac potassium, which belongs to a group of non-steroidal anti-inflammatory drugs (NSAIDs), acting as an anti-rheumatic, anti-inflammatory, analgesic, and antipyretic. The mechanism of action of Cataflam 50 involves the inhibition of prostaglandin biosynthesis, which plays a fundamental role in the pathogenesis of inflammation, pain, and fever. Cataflam 50 is used for the short-term treatment of the following acute conditions:
In the case of diagnosed heart disease or significant risk factors for heart disease, the treating doctor will periodically assess the patient's need for symptomatic treatment and their response to the medicine, especially if treatment lasts longer than 4 weeks. During treatment, regular blood tests should be performed in the case of any liver function disorders, kidney function disorders, and blood count abnormalities. Both liver function (transaminase levels), kidney function (creatinine levels), and blood count (white blood cell count, red blood cell count, and platelet count) should be monitored. The treating doctor will take into account the results of blood tests when deciding to discontinue treatment with Cataflam 50 or change the dose of the medicine.
Like other non-steroidal anti-inflammatory drugs (NSAIDs), Cataflam 50 should not be taken by people who may experience an asthma attack, hives, or acute rhinitis after taking acetylsalicylic acid or other prostaglandin synthesis inhibitors. The patient should inform their doctor about these diseases.
Before taking Cataflam 50, the patient should discuss the following with their doctor:
patients allergic to other substances (e.g., those who experience skin reactions, itching, or hives). The medicine should be administered with caution (preferably under medical supervision);
Before taking diclofenac, the patient should inform their doctor
The occurrence of side effects can be reduced by taking the medicine in the smallest effective dose and for no longer than necessary. The smallest dose of Cataflam 50 that relieves pain and/or inflammation should be used, and it should be taken for the shortest possible time to minimize the risk of side effects. If, at any point during treatment with Cataflam 50, the patient experiences symptoms suggesting heart or blood vessel problems, such as chest pain, shortness of breath, weakness, or slurred speech, they should immediately contact their doctor or visit the emergency department. Taking diclofenac may temporarily inhibit platelet aggregation. Before taking Cataflam 50, the patient should tell their doctor if they have recently undergone or are scheduled to undergo stomach or gastrointestinal surgery, as the medicine may sometimes cause delayed wound healing in the intestines after surgery.
The medicine should not be taken by children and adolescents under 14 years of age. For children and adolescents under 14 years of age, diclofenac is recommended in the form of suppositories, at a dose of 25 mg per day. Cataflam 50 should not be taken by children under 1 year of age.
Elderly patients may be more sensitive to the effects of the medicine than other adults. The patient should follow the recommendations in the leaflet and take the smallest effective dose, as recommended by the doctor, and report any side effects that occur during treatment to their doctor.
The patient should tell their doctor about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
The tablets should be swallowed whole with water, preferably before meals.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a baby, they should consult their doctor before taking this medicine. The patient should not take Cataflam 50 if they are in the last 3 months of pregnancy, as it may harm the unborn baby or cause complications during delivery. It may cause kidney and heart problems in the unborn baby. It may also increase the risk of bleeding in the patient and their baby and prolong or delay labor. During the first 6 months of pregnancy, the medicine should not be taken unless it is absolutely necessary and recommended by a doctor. If treatment is necessary during this period or when trying to conceive, the smallest effective dose should be used for the shortest possible time. From the 20th week of pregnancy, Cataflam 50 may cause kidney problems in the unborn baby if taken for more than a few days. This may lead to a decrease in the amount of amniotic fluid surrounding the baby (oligohydramnios) or narrowing of the arterial duct in the baby's heart. If treatment is necessary for a longer period, the doctor may recommend additional monitoring. The patient should not take Cataflam 50 while breastfeeding, as it may have a harmful effect on the baby. The doctor will discuss the potential risks of taking Cataflam 50 during pregnancy and breastfeeding with the patient. Taking Cataflam 50 may make it more difficult to conceive. If the patient plans to conceive or is having trouble conceiving, they should inform their doctor.
The effect of Cataflam 50 on the ability to drive or use machines is unlikely.
Cataflam 50 tablets contain sugar. If the patient has been diagnosed with intolerance to some sugars, they should consult their doctor before taking the medicine.
The medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means it is considered "sodium-free".
This medicine should always be taken exactly as directed by the doctor. If the patient has any doubts, they should consult their doctor or pharmacist. The patient should not exceed the recommended dose. If the patient is taking Cataflam 50 tablets for more than a few weeks, they should have regular medical check-ups to rule out any unnoticed side effects. The general recommendation is to adjust the dose individually and use the smallest effective dose for the shortest possible period. If the patient feels that the effect of the medicine is too strong or too weak, they should consult their doctor.
The recommended initial dose is 100 mg per day to 150 mg per day. In milder cases, a dose of 75 mg to 100 mg per day is considered sufficient. The tablets should be taken orally. The total daily dose should be divided into 2 to 3 doses, if necessary. The patient should not exceed the daily dose of 150 mg. In patients with primary dysmenorrhea, the initial dose of the medicine is 50 mg, which should be taken when the first symptoms appear, and then continued with a dose of 50 mg, taken up to three times a day, for several consecutive days, as needed. If a dose of 150 mg per day does not provide sufficient pain relief for two to three consecutive menstrual cycles, the treating doctor may recommend an initial dose of 100 mg and up to 200 mg per day, divided into 2 to 3 doses, during subsequent menstrual cycles. The patient should not exceed the dose of 200 mg per day. In the treatment of migraine, the initial dose of the medicine is 50 mg, which should be taken when the first symptoms of the disease appear. If pain relief is not sufficient within 2 hours of taking the first dose, an additional dose of 50 mg may be taken. If necessary, additional doses of 50 mg may be taken at intervals of 4 to 6 hours. The patient should not exceed the dose of 200 mg per day.
Due to the strength of the dose, Cataflam 50 is not recommended for children and adolescents under 14 years of age. For children and adolescents under 14 years of age, diclofenac is recommended in the form of suppositories, at a dose of 25 mg per day. In adolescents over 14 years of age, a dose of 75 mg to 100 mg per day, divided into 2 to 3 doses, is usually sufficient. The patient should not exceed the maximum daily dose of 150 mg. In children and adolescents (under 18 years of age), Cataflam 50 should not be taken to treat migraine.
The medicine should be taken with caution in elderly patients. In elderly patients and those with low body weight, the smallest effective dose is recommended.
The tablets should be swallowed whole with water, preferably before meals. The patient should not divide or chew the tablets.
Cataflam 50 should always be taken exactly as directed by the doctor. If the patient is taking Cataflam 50 for a long time, they should regularly consult their doctor to ensure that no side effects have occurred. If the patient has any doubts about how long to take the medicine, they should consult their doctor or pharmacist.
Overdosing on Cataflam 50 does not cause characteristic symptoms, but the following may occur: vomiting, gastrointestinal bleeding, diarrhea, dizziness, tinnitus, or seizures. In the case of significant poisoning, acute kidney failure and liver damage may occur. If the patient has taken more tablets than recommended, they should immediately consult their doctor, pharmacist, or visit the emergency department.
If the patient misses a dose, they should take it as soon as they remember. However, if more than half of the time has passed between two doses, they should not take the missed dose and should take the next dose according to the previous dosing schedule. The patient should not take a double dose to make up for the missed dose.
Like all medicines, Cataflam 50 can cause side effects, although not everybody gets them. The frequency of side effects is estimated as follows: very common (≥1/10); common (≥1/100 to <1>
Taking medicines like Cataflam 50 may be associated with a small increased risk of heart attack (myocardial infarction) or stroke. If the patient experiences any side effects, including those not listed in this leaflet, they should tell their doctor or pharmacist. If any of the side effects get worse or if the patient experiences any side effects not listed in this leaflet, they should tell their doctor or pharmacist.
These uncommon side effects may occur in 1-10 patients per 1,000, especially when taking high daily doses (150 mg) for a long time
If the patient is taking Cataflam 50 for more than a few weeks, they should regularly consult their doctor to ensure that no side effects have occurred.
Reporting suspected side effects If the patient experiences any side effects, including those not listed in this leaflet, they should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety Monitoring, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl. Side effects can also be reported to the marketing authorization holder. By reporting side effects, more information can be gathered on the safety of the medicine.
Keep out of the sight and reach of children. Do not take this medicine after the expiry date stated on the carton and blister. Store in a temperature below 30°C. Keep away from moisture.
One pack contains 10 coated tablets.
Novartis Poland Sp. z o.o., ul. Marynarska 15, 02-674 Warsaw, tel. +48 22 37 54 888
Novartis Pharma GmbH, Roonstrasse 25, 90429 Nürnberg, Germany, Novartis Farmacéutica S.A., Gran Via de les Corts Catalanes, 764, 08013 Barcelona, Spain, Novartis Poland Sp. z o.o., ul. Marynarska 15, 02-674 Warsaw
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for Cataflam 50 – subject to medical assessment and local rules.